The appointment of Prof Chow and his standing in the Asian liver community has got me thinking that maybe liver sales will outstrip pancreatic sales.
In $$ terms the liver cancer market is bigger.
I am attaching a link to the sirtex trail, of which Prof Chow is the lead clinical chairman. Have a look at the participating centres down the left hand side when you open the link attached at the bottom of this post. He is doing liver business in a lot more of Asia than just Singapore hospitals.
In todays announcement Prof Chow said;
"I am delighted to be working again with the Team at OncoSil, and look forward to my role as Chairman of the HCC Scientific Advisory Board in developing the HCC program. Every now and again you come across a new and exciting approach in medicine that really stands out. OncoSil is exactly that for primary liver cancer I look forward to utilising my skills and expertise in this area to help realise this potential."
I don't think the market has woken up to the fact that the filing for liver cancer in addition to pancreatic cancer strengthens its filing position and carries no additional risk as was stated in Mondays filing announcement.
I think Ce mark for liver will be huge.
http://www.sirvenib.com/
(20min delay)